Related Experiment Video
Updated: Mar 12, 2026
Author Spotlight: Modeling Brain Tumors In Vivo Using Electroporation-Based Delivery of Plasmid DNA Representing Patient Mutation Signatures
Published on: June 23, 2023
Successful Treatment of a Patient with Glioblastoma and a Germline POLE Mutation: Where Next?
Alexandra Snyder1,2, Jedd D Wolchok3,4,5,6
1Weill Cornell Medical College, New York, New York.
Abstract:
Hypermutation and elevated neoantigen count in glioblastoma occurred in a patient harboring a germline POLE mutation and are associated with a clinical and antitumor immune response to PD-1 blockade. Cancer Discov; 6(11); 1210-11. ©2016 AACR.See related article by Johanns et al., p. 1230.
Insights
A patient with glioblastoma and a germline POLE mutation experienced hypermutation and increased neoantigens. This was linked to a positive immune response and clinical benefit from PD-1 blockade therapy.
Area of Science:
- Oncology
- Genetics
- Immunology
Background:
- Glioblastoma is an aggressive brain tumor with limited treatment options.
- Germline mutations in DNA polymerase proofreading genes, like POLE, can lead to genomic instability and cancer.
- The role of specific germline mutations in glioblastoma's response to immunotherapy is not fully understood.
Observation:
- A glioblastoma patient presented with a germline POLE mutation.
- This patient exhibited a hypermutated tumor phenotype with a high neoantigen load.
- The tumor showed signs of an active antitumor immune response.
Findings:
- The germline POLE mutation was associated with extensive tumor DNA mutations.
- The elevated neoantigen count correlated with the degree of hypermutation.
- The patient demonstrated a significant clinical response and antitumor immunity following PD-1 blockade treatment.
Implications:
- Germline POLE mutations may predict response to immune checkpoint inhibitors in glioblastoma.
- Understanding the genetic basis of hypermutation can guide immunotherapy strategies.
- Targeting DNA repair pathways could enhance cancer treatment efficacy.
